INDICATIONS AND USAGE 

Chronic Myeloid Leukemia (CML)
Ponatinib is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T3151 mutation.
Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)
Ponatinib is indicated in adult patients with Philadelphia chromo- some positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T3151 mutation,
DOSAGE AND ADMINISTRATION
Therapy should be initiated by a physician experienced in the diagnosis and treatment of patients with leukemia. Haemato- logic support such as platelet transfusion and haematopoietic growth factors can be used during treatment if clinically indicated.
Before starting treatment with ponatinib, the cardiovascular status of the patient should be assessed, including history and physical examination, and cardiovascular risk factors should be actively managed. Cardiovascular status should continue to be monitored and medical and supportive therapy for conditions that contribute to cardiovascular risk should be optimised during treatment with ponatinib.

FIND A PRODUCT